Prevalence of thromogenic gene mutations in women with recurrent miscarriage: A retrospective study of 1,507 patients.
10.5468/ogs.2014.57.6.513
- Author:
Adnan INCEBIYIK
1
;
Nese Gul HILALI
;
Aysun CAMUZCUOGLU
;
Hakan CAMUZCUOGLU
;
Halit AKBAS
;
Avni KILIC
;
Mehmet VURAL
Author Information
1. Department of Gynecology and Obstetrics, Harran University Faculty of Medicine, Sanliurfa, Turkey. dr.aincebiyik@gmail.com
- Publication Type:Original Article
- Keywords:
Factor V Leiden;
Methylenetetrahydrofolate reductas;
Prevalence;
Prothrombin;
Recurrent pregnancy loss
- MeSH:
Abortion, Habitual*;
Factor V;
Female;
Humans;
Incidence;
Mass Screening;
Methylenetetrahydrofolate Reductase (NADPH2);
Mutation Rate;
Obstetrics;
Polymerase Chain Reaction;
Pregnancy;
Prevalence*;
Prothrombin;
Retrospective Studies*;
Turkey
- From:Obstetrics & Gynecology Science
2014;57(6):513-517
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Thromogenic gene mutations has been thought to be associated with recurrent pregnancy loss in women in Turkey. The aim of this study was to investigate the prevalence of thromogenic gene mutations such as factor V Leiden (FVL, G1691T), prothrombin (G20210A), and the methylene tetrahydrofolate reductase (MTHFR, C677T) mutation in women with recurrent pregnancy loss. METHODS: This descriptive study was carried out in the Department of Obstetrics and Gynaecology, Harran University School of Medicine, and included a total of 1,507 women with histories of recurrent pregnancy loss between January 2010 and June 2013. The mutations were assessed by using the polymerase chain reaction. RESULTS: The homozygous mutation frequencies of FVL, prothrombin, and MTHFR were found to be 3 (0.20%), 0 and 125 (8.29%), and the heterozygous mutation frequencies were 83 (5.51%), 61 (4.05%), and 612 (40.61%), respectively. Among the 86 FVL mutation patients, 38 also had accompanying prothrombin and MTHFR mutations. CONCLUSION: Since the homozygous forms of the FVL-prothrombin gene mutations have low incidences and MTHFR mutation is similar to a healthy population, preconceptional thromogenic gene mutations screening seems to be controversial.
